Bergisch Gladbach, 02.06.2008 – Girindus AG sold today its industrial activities at the production site in Halle-Kuensebeck. Acquirer is Central Glass Germany GmbH, an affiliate of Central Glass Co., Ltd., Japan, with an annual turnover of nearly 1.2 Billion Euro and with a history of over 70 years. Central Glass Germany GmbH takes over process development, upscaling, cGMP production of active pharmaceutical ingredients as well as the fine chemical business and all related analytical activities. The works council and the employees at the Künsebeck site have been informed immediately. Both parties agreed not to disclose the purchase price.

"With this acquisition we are building the foundation for entering the European market for the contract manufacturing of active pharmaceutical ingredients “, said Masamichi Maruta, Managing Director of Central Glass Germany GmbH.
“I am especially happy for the employees, who retain their jobs. Girindus now can fully focus on the turnaround and thus securing the future of the Girindus Group“, commented Dr. Hans Hiller, Executive Vice President Operation of Girindus AG, on the successful conclusion of the contractual negotiations.

In addition to maintaining the jobs related to the transferred activities this transaction gives the existing customers continued access to products and services. For Girindus this solution is economically better than closing the site.

As already announced in January the separation is associated with a restructuring of the administration functions in Bensberg.

About Central Glass:
Central Glass is specialised in the manufacture and sale of flat glass, processed glass, building materials and other glass products; soda, chlorine, organic and inorganic fluorine compounds, fertilizers and other chemical products; glass fiber products; synthetic resins, as well as the production of active pharmaceutical ingredients which is the interface to the production plant in Kuensebeck. The headquarter of Central Glass is in Tokyo.

About Girindus:
Girindus is developing synthesis for active pharmaceutical ingredients and is a leading provider of therapeutic oligonucleotides. The company operates an FDA inspected site in Cincinnati, USA. A product line of active cosmetic ingredients is in development.


Contact:
Ralf Penner
Investor Relations
Girindus AG, 51427 Bergisch Gladbach
T: +49 – (0)2204 – 926 - 900
F: +49 – (0)2204 – 926 - 990
rpenner@girindus.com

back to top